SCHEMBL3230607

SCHEMBL3230607

CN(C)C1(C(NC(=O)c2c(C(F)(F)F)cccc2C(F)(F)F)c2ccccc2)CCCC1

nearest known ligand 0.45

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 18/20 0.45
SLC6A5 Q9Y345 1/20 0.40
HDAC4 P56524 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3240532 0.93 ITGA4 (0.45) SLC6A9SLC6A5HDAC4
SCHEMBL3242349 0.93 SLC6A9 (0.48) SLC6A9SLC6A5
SCHEMBL3231206 0.86 SLC6A9 (0.62) SLC6A9
SCHEMBL3237991 0.85 SLC6A9 (0.40) SLC6A9SLC6A5
SCHEMBL3233224 0.85 SLC6A9 (0.45) SLC6A9
SCHEMBL3237575 0.85 SLC6A9 (0.61) SLC6A9
SCHEMBL3240614 0.84 SLC6A9 (0.56) SLC6A9SLC6A5
SCHEMBL3243701 0.84 CTSS (0.51) SLC6A9
SCHEMBL3238143 0.84 SLC6A9 (0.39) SLC6A9
SCHEMBL3239398 0.83 SLC6A9 (0.55) SLC6A9SLC6A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287547-A1 Glycine Transport Inhibitors SLC18A2, SLC6A5, SLC1A2 SLC6A9 13/4885SLC6A5 2/4885HDAC4 4056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.